Acarbose Longevity: Mechanisms, Evidence, and Research Roadmap

Wed, 01 Apr 2026 00:00:00 +0000

Cluster context: This article belongs to the Metabolic and Prescription Longevity Drugs cluster. For the broader overview, start with Prescription Longevity Drugs: Clinical Guide To Preventive Medicine.

A diabetes drug originally designed to control blood sugar is now generating serious interest in aging research circles. Acarbose, an alpha glucosidase inhibitor that slows carbohydrate digestion, has demonstrated remarkable lifespan extension in preclinical models. This article breaks down what we know, what we don’t, and what comes next.

Acarbose Longevity: Mechanisms, Evidence, and Practical Protocols

Wed, 14 Jan 2026 00:00:00 +0000

Cluster context: This article belongs to the Metabolic and Prescription Longevity Drugs cluster. For the broader overview, start with Prescription Longevity Drugs: Clinical Guide To Preventive Medicine.

The search for interventions that slow aging has moved from folklore to rigorous science. Among the compounds showing genuine promise, acarbose stands out with some of the most reproducible results in longevity research. Originally developed for diabetes management, this prescription medication is now attracting attention from researchers and biohackers seeking to extend lifespan through metabolic manipulation.

Acarbose Lifespan Study on Longetivities

Acarbose Longevity: Mechanisms, Evidence, and Research Roadmap

Acarbose Longevity: Mechanisms, Evidence, and Practical Protocols